Prescient Therapeutics Limited

ASX:PTX Stock Report

Market Cap: AU$34.6m

Prescient Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Prescient Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth16.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

Mar 12
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Nov 14
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Aug 01
Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Prescient Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:PTX - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20233-8-8-8N/A
9/30/20233-7-7-7N/A
6/30/20232-7-6-6N/A
3/31/20232-6-6-6N/A
12/31/20222-5-5-5N/A
9/30/20222-5-5-5N/A
6/30/20222-5-4-4N/A
3/31/20222-5-4-4N/A
12/31/20211-5-4-4N/A
9/30/20211-5-4-4N/A
6/30/20211-4-4-4N/A
3/31/20211-4-4-4N/A
12/31/20201-3-3-3N/A
9/30/20201-3-3-3N/A
6/30/20201-3-2-2N/A
3/31/20201-4-2-2N/A
12/31/20192-4-2-2N/A
9/30/20192-4-3-3N/A
6/30/20192-4-4-4N/A
3/31/20191-3-3-3N/A
12/31/20181-3-3-3N/A
9/30/20181-3-2-2N/A
6/30/20181-3-2-2N/A
3/31/20181-3-3-3N/A
12/31/20171-3-3-3N/A
9/30/20171-3N/A-3N/A
6/30/20171-3N/A-3N/A
3/31/20171-2N/A-3N/A
12/31/20161-2N/A-2N/A
9/30/20161-2N/A-2N/A
6/30/20161-2N/A-2N/A
3/31/20161-2N/A-2N/A
12/31/20151-2N/A-2N/A
9/30/20151-2N/A-2N/A
6/30/20150-2N/A-2N/A
3/31/20150-2N/AN/AN/A
12/31/20140-2N/A-1N/A
9/30/20140-2N/A-1N/A
6/30/20140-2N/A-1N/A
3/31/20140-1N/AN/AN/A
12/31/20130-1N/A-1N/A
9/30/201300N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PTX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if PTX's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if PTX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PTX's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if PTX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.